Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion
- PMID: 22381903
- DOI: 10.1016/j.ijrobp.2011.12.024
Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion
Abstract
Purpose: The present study evaluates the influence of portal vein (PV) vs. inferior vena cava (IVC) tumor thrombosis sites on the effectiveness of external-beam radiation therapy (EBRT) in advanced hepatocellular carcinoma (HCC) with macrovascular invasion.
Methods and materials: We retrospectively reviewed 181 HCC patients with PV and/or IVC tumor thrombi who were referred for EBRT at our institution between 2000 and 2009. EBRT was designed to focus on the tumor thrombi with or without primary intrahepatic tumors to deliver a median total conventional dose of 50 Gy (range, 30-60 Gy). Predictors of survival were identified using univariate and multivariate analyses.
Results: The median survival was 10.2, 7.4, 17.4, and 8.5 months for patients with PV branch, PV trunk, IVC, and PV plus IVC tumor thrombosis, respectively. Unfavorable pretreatment predictors were associated by multivariate analysis with lower albumin and higher α-fetoprotein levels, poorer Child-Pugh liver function classification, multiple intrahepatic foci, lymph node metastases, thrombus location, less chance to receive post-EBRT transarterial chemoembolization (TACE) and the two-dimensional EBRT technique. In comparison to patients with PV tumor thrombosis, patients with IVC thrombi had a higher occurrence of solitary intrahepatic lesions (p = 0.027), well-controlled intrahepatic tumors (p < 0.001), and a better response to EBRT (p < 0.001), and they were more likely to receive post-EBRT TACE (p = 0.033).
Conclusions: In HCC, patients with IVC thrombus treated with EBRT had a better response rate and longer survival than those with PV thrombus.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus.Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):432-43. doi: 10.1016/j.ijrobp.2004.05.025. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667964
-
Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2004-11. doi: 10.1016/j.ijrobp.2011.03.019. Epub 2011 May 27. Int J Radiat Oncol Biol Phys. 2012. PMID: 21621346
-
Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus.Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):180-7. doi: 10.1016/j.ijrobp.2009.07.1730. Epub 2009 Nov 18. Int J Radiat Oncol Biol Phys. 2010. PMID: 19926229
-
Radiation therapy for hepatocellular carcinoma: from palliation to cure.Cancer. 2006 Apr 15;106(8):1653-63. doi: 10.1002/cncr.21811. Cancer. 2006. PMID: 16541431 Review.
-
Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population.Biosci Trends. 2019 Mar 14;13(1):10-22. doi: 10.5582/bst.2018.01261. Epub 2019 Feb 24. Biosci Trends. 2019. PMID: 30799321 Review.
Cited by
-
Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma.BMC Cancer. 2019 Jun 10;19(1):560. doi: 10.1186/s12885-019-5654-9. BMC Cancer. 2019. PMID: 31182065 Free PMC article.
-
Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.Int Surg. 2015 May;100(5):908-14. doi: 10.9738/INTSURG-D-14-00133.1. Int Surg. 2015. PMID: 26011214 Free PMC article.
-
Three-dimensional conformal radiotherapy for locally advanced hepatocellular carcinoma with portal vein tumour thrombosis: evaluating effectiveness of the model for end-stage liver disease (MELD) score compared with the Child-Pugh classification.Br J Radiol. 2016 Jul;89(1063):20150945. doi: 10.1259/bjr.20150945. Epub 2016 May 10. Br J Radiol. 2016. PMID: 27164029 Free PMC article.
-
Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma.Cancers (Basel). 2024 Feb 19;16(4):838. doi: 10.3390/cancers16040838. Cancers (Basel). 2024. PMID: 38398229 Free PMC article.
-
Inferior vena cava tumor thrombus that directly infiltrated from paracaval lymph node metastases in a patient with recurrent hepatocellular carcinoma.World J Surg Oncol. 2013 Aug 6;11:177. doi: 10.1186/1477-7819-11-177. World J Surg Oncol. 2013. PMID: 23915104 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous